Biorepository Core B

Case Western Reserve University, Cleveland OH

Investigators

Linked publications & trials

Abstract

BIOREPOSITORY CORE B PROJECT SUMMARY BIOREPOSITORY CORE B PROJECT SUMMARY Dr. Florian Rieder is core director. Dr. Claudio Fiocchi serves as associate director ,and Drs. Pranab Mukherjee, and Jennifer Ko as technical directors. The specific goals include: 1) Procure, process, and distribute tissue and cells from surgical specimens and biopsies, as well as blood, serum, plasma, DNA, urine and stools, from a diverse and inclusive group of individuals with gastrointestinal or liver inflammation and controls for use in IRB-approved projects of our DDRCC investigators; 2) Provide phenotypic, genotypic, clinical and demographic information of the biosamples; 3) Provide isolation, purification, culture and use of most types of gastrointestinal tract cells, including intestinal organoids and organoid monolayers and fresh mesenteric immune and non-immune cells; 4) Continue to develop state-of-the-art methods for single cell biology, including single cell digestion protocols, preparation, and analysis of intestinal and liver tissues. 5) Advise, teach, and supervise investigators on principles, methods, analysis, and experimental design; 6) Monitor Core services and continuously evaluate the needs of the diverse and inclusive group of DDRCC members to maximally benefit their research priorities, and 7) Provide all above services in the most cost-effective and least time-consuming manner. In the nine years since its inception, the Biorepository Core has been able to provide Cleveland DDRCC investigators and other qualified investigators with the type, size, or number of biospecimens required for their studies, as well as support DDRCC investigators with training and logistics. This success was achieved by the careful enactment of the specific goals. In the last reporting period, we implemented a state-of-the-art laboratory information system (LabVantage Solutions-LV), which tracks origin of samples, clinical information, genealogy of samples, and sample retrieval and distribution, which improved quick identification, diagnosis and delivery, and formal access to clinical data for interpretation of the experimental results. A new benefit of the Core focuses on its technical services around the theme of digestive and liver inflammation to include: 1) generation of intestinal organoids and organoid monolayers from Crohn’s disease tissues of different phenotypes, such as strictures or the ileal-anal pouch anastomosis (IPAA), 2) single cell digestion protocols, preparation and analysis from full thickness tissues from Crohn’s disease, ulcerative colitis, IPAA and controls, 3) isolation of fresh mesenteric immune (mononuclear cells) and non- immune (adipocytes, pre-adipocytes, fibroblasts, endothelial cells), 4) 3-dimensional (3D) decellularized intestinal extracellular matrix platforms, 5) unique gut-on-a-chip models and 3D multicellular liver models for cell interaction studies and 6) access to well-established biobanks for IBD, Barrett’s esophagus and esophageal adenocarcinoma, alcoholic and non-alcoholic cirrhosis, and specimens from people living with HIV and digestive/liver inflammation. Overall, the Core benefits DDRCC members by providing unique and high quality biosamples and services.